Patent application number | Description | Published |
20080254085 | Degradable Polymers Incorporating Gamma-Butyrolactone - Disclosed herein are implantable medical devices having controlled release biodegradable polymer coatings thereon wherein the polymer is formed from ring opening of γ-butyrolactone and at least one additional monomer selected from the group consisting of trimethylene carbonate, lactide, polyethylene glycol, glycolide, the monomers formed from ring opening of ε-caprolactone, 4-tert-butyl caprolactone, and N-acetyl caprolactone, and combinations thereof, and at least one drug releasable from the biodegradable polymer. Also disclosed are implantable medical devices form of the biodegradable polymers and processes for forming the polymers. | 10-16-2008 |
20090238815 | Nondegradable Hydrogels For Medical Device Application - Disclosed are nondegradable hydrogels used to coat or form at least a portion of a medical device. The hydrogels may be formed from functionalized PEG based macromers. These hydrogels are easy to sterilize, transport and store. Methods of forming these hydrogels as described herein are included. | 09-24-2009 |
20090294049 | Biodegradable Adhesive Hydrogels - Disclosed are methods for forming adhesive hydrogels on tissue surfaces comprising applying to a first tissue surface at a treatment site a first mixture comprising at least one photosensitive molecule and at least one initiator, exposing the first tissue surface to light having a wavelength sufficient to activate the photosensitive molecule to form an activated tissue surface, applying to the activated tissue surface or to a second surface a second mixture comprising at least one macromer, at least one cross-linking agent, and at least one initiator and contacting the first tissue surface with the second surface thus adhering the first tissue surface to the second surface through macromer cross-linking and resulting adhesive hydrogel formation. | 12-03-2009 |
20110104234 | Biodegradable Modified Carpolactone Polymers for Fabrication and Coating Medical Devices - Disclosed herein are biodegradable modified caprolactone polymers for coating and forming medical devices. The properties of the polymers are fine tuned for optimal performance depending on the medical purpose. Moreover, the polymers are suitable for the controlled in situ release of drugs at the treatment site. | 05-05-2011 |
20110150966 | DEGRADABLE POLYMERS INCORPORATING GAMMA-BUTYROLACTONE - Disclosed herein are implantable medical devices having controlled release biodegradable polymer coatings thereon wherein the polymer is formed from ring opening of γ-butyrolactone and at least one additional monomer selected from the group consisting of trimethylene carbonate, lactide, polyethylene glycol, glycolide, the monomers formed from ring opening of ε-caprolactone, 4-tert-butyl caprolactone, and N-acetyl caprolactone, and combinations thereof, and at least one drug releasable from the biodegradable polymer. Also disclosed are implantable medical devices form of the biodegradable polymers and processes for forming the polymers. | 06-23-2011 |
Patent application number | Description | Published |
20110098804 | STENTED TRANSCATHETER PROSTHETIC HEART VALVE DELIVERY SYSTEM AND METHOD - A percutaneous stented valve delivery device including an inner shaft, a sheath, and a delivery capsule. The sheath slidably receives the inner shaft. A capsule proximal zone is attached to the sheath. A capsule distal zone is configured to transition between normal and flared states. A diameter of the distal zone is greater in the flared state, and the capsule includes a shape memory component that naturally assumes the normal state. The device is operable to perform a reversible partial deployment procedure in which a portion of the prosthesis is exposed distal the capsule and allowed to radially expand. Subsequently, with distal advancement of the capsule, the distal zone transitions to the flared state and imparts a collapsing force onto the prosthesis, causing the prosthesis to radially collapse and become recaptured within the delivery capsule. The capsule can include a laser cut tube encapsulated by a polymer. | 04-28-2011 |
20120259314 | Apparatus and Methods for Recanalization of a Chronic Total Occlusion - A method of recanalizing a chronic total occlusion (CTO) is disclosed. A catheter with a guidewire slidingly received therein is positioned proximally adjacent to the CTO. An occlusion weakening therapy effective to quickly soften and/or loosen the CTO is delivered to the CTO via the catheter. The occlusion weakening therapy includes at least one enzyme and a chelating agent which are selectively deliverable either together or separately depending on the type of material encountered by the guidewire. According to various methods, the enzyme(s) may be delivered if tissue is encountered, the chelating agent may be delivered if calcification is encountered, and both enzyme(s) and chelating agent(s) may be delivered if a fibrous cap is encountered. The distal end of the guidewire may be advanced into the CTO shortly after delivery of the occlusion weakening therapy and is manipulated through the CTO until the guidewire successfully crosses the CTO. | 10-11-2012 |
20130090741 | Magnesium Alloys for Bioabsorbable Stent - A stent is formed from a magnesium alloy that consists essentially of: 0-10 weight % rare earth element; 0-5 weight % Li; 0-1 weight % Mn; 0-1 weight % Zr; and balance Mg, or the stent is formed from a magnesium alloy that consists essentially of: 0-5 weight % rare earth element; 0-8 weight % Li; 0-1 weight % Mn; 0-1 weight % Sn; 0-3 weight % Al; 0-4 weight % Zn; and balance Mg. | 04-11-2013 |
20130103161 | Iron Based Alloys for Bioabsorbable Stent - A stent includes an iron-based alloy that consists essentially of: Fe—X—Y, wherein X is at least one austenite stabilizing element selected from the group consisting of Co, Ni, Mn, Cu, Re, Rh, Ru, Ir, Pt, Pd, C, and N, and wherein Y is at least one corrosion-activator species selected from the group consisting of Au, and Pd. | 04-25-2013 |
20130192611 | MEDICAL DEVICE FIXATION - A fixation device configured to anchor an implantable medical device within a patient includes a temporary biodegradable fixation mechanism configured to secure the device after implantation until the temporary fixation mechanism biodegrades and a chronic fixation mechanism configured to promote tissue growth that secures the device to tissue of the patient before the temporary fixation mechanism biodegrades. | 08-01-2013 |
20130284310 | APPARATUS AND METHODS FOR FILLING A DRUG ELUTING MEDICAL DEVICE VIA CAPILLARY ACTION - Methods and apparatus are disclosed for filling a therapeutic substance or drug within a hollow wire that forms a stent. The stent is placed within a chamber housing a fluid drug formulation. During filling, the chamber is maintained at or near the vapor-liquid equilibrium of the solvent of the fluid drug formulation. To fill the stent, a portion of the stent is placed into contact with the fluid drug formulation until a lumenal space defined by the hollow wire is filled with the fluid drug formulation via capillary action. After filling is complete, the stent is retracted such that the stent is no longer in contact with the fluid drug formulation. The solvent vapor pressure within the chamber is reduced to evaporate a solvent of the fluid drug formulation. A wicking means may control transfer of the fluid drug formulation into the stent. | 10-31-2013 |
20140277396 | Bioabsorbable Stent With Hydrothermal Conversion Film and Coating - A stent includes a bioabsorbable metal, a hydrothermal conversion film covering the bioabsorbable metal, and a coating covering the hydrothermal conversion film. A method for manufacturing a stent includes forming a stent body comprising a bioabsorbable metal, forming a hydrothermal conversion film over surfaces of the stent body, and coating the hydrothermal conversion film with an overcoat. | 09-18-2014 |
Patent application number | Description | Published |
20100124533 | Large Animal Model for Human-Like Advanced Atherosclerotic Plaque - An animal model for cardiovascular disease comprising one or more vascular plaque lesions formed at selected sites within a vascular segment of a nonhuman mammal. The vascular plaque lesion is formed by administering a hypercholesterolemic diet to the nonhuman mammal, inflicting an injury to the vascular wall at the selected site after a predetermined exposure to the hypercholesterolemic diet, and applying a hydrogel to the injured vascular wall. Another aspect of the invention provides a method for evaluating a test compound for an effect on atherosclerotic lesion formation comprising administering to a nonhuman mammal a hypercholesterolemic diet, and, after a defined period of time, isolating a segment of a blood vessel using a balloon catheter, inflicting an injury to the vascular wall within the isolated segment, and applying a hydrogel within the vascular segment. The method further comprises forming a vascular plaque lesion on the vascular wall at the site of the injury, delivering the test compound to the nonhuman mammal, and monitoring atherosclerotic lesion size and composition at the injured site after a defined period of exposure to the test compound. | 05-20-2010 |
20100125326 | Braided Stent With a Shortenable Tether - The braided stent with a shortenable tether of the present invention includes a stent for use in a vessel having a vessel wall including a braided stent framework having a first framework end and a second framework end; and a plurality of shortenable tethers, each of the plurality of shortenable tethers having a first tether end and a second tether end, the plurality of shortenable tethers being disposed along a length of the braided stent framework and fixed to the braided stent framework at the first tether end and the second tether end. The plurality of shortenable tethers shorten in response to vessel conditions to urge the first framework end and the second framework end toward each other when the stent is deployed in the vessel to urge a circumference of the braided stent framework toward the vessel wall. | 05-20-2010 |
20100152831 | Implantable Medical Devices Having Multiblock Copolymers - Provided herein are implantable medical devices comprising a biodegradable multiblock copolymer comprising at least three blocks; wherein the at least three blocks includes at least one inner block and two end blocks; further wherein each of the at least one inner block comprises monomers selected from the group consisting of e-caprolactone, r-butylactone, trimethylene carbonate, caprolactone derivatives, P-Dioxanone, and combinations thereof; and further wherein each of the end blocks comprises monomers selected from the group consisting of l-lactide, D-lactide, glycolide, L,D-lactide, and combinations thereof. | 06-17-2010 |
20100158981 | Block Biodegradable Copolymers for Medical Devices - Disclosed herein are implantable medical devices comprising controlled release biodegradable block copolymers or coated with controlled release block copolymers and at least one drug releasable from the block copolymer. The controlled release block copolymers comprise least two blocks selected from the group consisting of polyesters, polyethers, and polyurethanes. | 06-24-2010 |
20100262228 | Implantable Medical Devices Having Bioabsorbable Primer Polymer Coatings - The present disclosure generally relates to implantable medical devices having a metallic surface coated with a bioabsorbable primer polymer layer under a bioabsorbable drug polymer layer. Thus, in addition to the degradation of the drug polymer layer, there is degradation of the primer layer. The underlying metallic framework may or may not degrade depending on whether bioabsorbable or biostable metals are chosen. | 10-14-2010 |
20120067455 | Apparatus and Methods for Loading a Drug Eluting Medical Device - Methods and apparatus are disclosed for loading a therapeutic substance or drug within a lumenal space of a hollow wire having a plurality of side openings along a length thereof that forms a hollow drug-eluting stent with a plurality of side drug delivery openings. Loading a drug within the lumenal space of the hollow stent includes a drug filling step, in which the drug is mixed with a solvent or dispersion medium. The lumenal space may be filled with the drug solution or suspension in a reverse fill process and/or a forward fill process. After the drug filling step, a solvent or dispersion medium extracting step is performed to extract the solvent or dispersion medium from within the lumenal space such that only the drug remains within the hollow stent. A stent cleaning step may be performed to an exterior surface of the hollow stent. | 03-22-2012 |